Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3H2184
Wed, 10.08.2022
Epigenomics AG
Epigenomics AG Reports Financial Results for the First Six Months of 2022
Berlin (Germany) and San Diego, CA (U.S.A.), August 10, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2022.
Key figures
Total revenue increased slightly from EUR 22 [ … ]
Wed, 10.08.2022
Epigenomics AG
Epigenomics AG Reports Financial Results for the First Six Months of 2022
Berlin (Germany) and San Diego, CA (U.S.A.), August 10, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the second quarter and first half of 2022.
Key figures
Total revenue increased slightly from EUR 22 [ … ]
Wed, 11.05.2022
Epigenomics AG
Epigenomics AG Reports Financial Results for the First Quarter of 2022
Berlin (Germany) and San Diego, CA (U.S.A.), May 11, 2022 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first three months of 2022.
Financial key figures
Revenues in the first quarter 2022 increased slight [ … ]
Thu, 24.03.2022
Epigenomics AG
Epigenomics AG Reports Financial Results for Fiscal Year 2021
Total revenue of EUR 6.2 million, adjusted EBITDA of EUR -1.8 million
FDA clinical trial for Epi proColon "Next Gen" expected to start with patient enrollment this summer and to take two years to complete; publication of preliminary data is anticipated
Company evaluating multiple fi [ … ]
Mon, 24.01.2022
Epigenomics AG
Supervisory Board of Epigenomics AG Retains Greg Hamilton as Chief Executive Officer Through Development of Epi proColon "Next-Gen" Colorectal Cancer Screening Test
Greg Hamilton retained as CEO through 2025
Appointment underscores Epigenomics' commitment to the company's enhanced blood-based colorectal cancer screening test, Epi proColon "Next-G [ … ]
Tue, 14.12.2021
Epigenomics AG
Supervisory Board of Epigenomics AG appoints Jens Ravens as Chief Financial Officer
Jens Ravens is an internationally experienced leader with in-depth experience in Controlling, Finance, M&A, IT, Legal, and Human Resources
New Chief Financial Officer to join Epigenomics on February 1, 2022
Berlin (Germany) and San Diego, CA (U.S.A.), Decembe [ … ]
Thu, 18.11.2021
Epigenomics AG
Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer
Dr. Andrew Lukowiak is a proven senior executive with deep technology and development expertise
Appointment underscores Epigenomics' commitment to the opportunity for Epi proColon "Next-Gen", the company's enhanced blood-based colorectal ca [ … ]
Wed, 10.11.2021
Epigenomics AG
Epigenomics AG publishes financial results for the first nine months 2021
Berlin (Germany) and San Diego, CA (U.S.A.), November 10, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") today reported financial results (IFRS, unaudited) for the first nine months of 2021.
9M 2021 FINANCIAL RESULTS
Total revenue in the first nine months o [ … ]
Thu, 07.10.2021
Epigenomics AG
Epigenomics AG: EVP of Finance Albert Weber leaves the Company
Berlin (Germany) and San Diego, CA (U.S.A.), October 7, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company") announces that Executive Vice President Finance Albert Weber will resign from his position as member of the Executive Board of Epigenomics AG as of [ … ]
Mon, 13.09.2021
Epigenomics AG
NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA
Press Release
Epigenomics AG places maximum number of mandatory convertible bonds with a total volume of EUR 16.5 million
Berlin, September 13, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the [ … ]